Om du vill rapportera en biverkning gällande en av Lillys produkter, kontakta oss via e-post på DK_PHv@lilly.com eller på telefon +45 4526 6040. Har du ytterligare medicinska frågor gällande en av Lillys produkter, kontakta oss via länken ovan.
Forsteo ® (teriparatid)
Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska
COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1
Lilly has not studied the use of teriparatide in patients with COVID-19 nor in patients at risk of contracting COVID-19.
Risk of Developing COVID-19 in Patients with Osteoporosis
For further information regarding the risk of contracting coronavirus to people with osteoporosis and those taking osteoporosis medications, please refer to COVID-19 and osteoporosis on the IFO website 2 and local authorities.
Summary of Product Characteristics
According to the prescribing information, Forsteo may cause adverse reactions similar to symptoms of COVID-19. There have been reported adverse reactions in adults in teriparatide clinical trials and post-marketing spontaneous reports:
Common (≥ 1/100 to <1/10): Dyspnoea, Fatigue, Chest pain
Uncommon (≥ 1/1,000 to <1/100): Emphysema
Rare (≥ 1/10,000 to <1/1,000): Possible allergic events soon after injection: acute dyspnoea, oro/facial oedema, generalised urticaria, chest pain, oedema (mainly peripheral).3
Infectious Disease Resources for COVID-19
For current information on COVID-19, please refer to
Coronavirus disease (COVID-19) outbreak on the WHO website, and
1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
2. COVID-19 and osteoporosis. International Osteoporosis Foundation. Accessed March 27, 2020. https://www.iofbonehealth.org/news/covid-19-and-osteoporosis
4. Coronavirus disease (COVID-19) outbreak. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019
5. Coronavirus (COVID-19). Centers for Disease Control and Prevention. Accessed March 17, 2020. https://www.cdc.gov/coronavirus/2019-ncov/index.html
CDC = Centers for Disease Control and Prevention
COVID-19 = coronavirus disease 2019
Lilly = Eli Lilly and Company
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
WHO = World Health Organization
IFO = International Osteoporosis Foundations
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Datum fӧr senaste ӧversyn 2020 M03 17